Summary
36.57 1.29(3.66%)07/16/2025
Vaxcyte, Inc. (PCVX)
PCVX reported last earnings on 2025-05-07 after the market. An EPS of $-1.04 was observed compared to an estimated EPS of $-1.02, resulting in a surprise value of $-0.02. A revenue of $0 million was observed compared to an estimated revenue of $0 million, resulting in a surprise value of $0 Million.
Vaxcyte, Inc. (PCVX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 3.66 | 0.91 | 6.52 | 25.58 | -58.36 | -56.07 | 26.10 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C+ |
| Recommended Rating | Sell |
| DCF | Neutral |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Neutral |
| P/E | Strong Sell |
| P/B | Buy |
Earnings
| Trading Data | ||
| Close | 36.57 | |
| Open | 35.73 | |
| High | 36.79 | |
| Low | 35.52 | |
| Volume | 1,166,425 | |
| Change | 1.29 | |
| Change % | 3.66 | |
| Avg Volume (20 Days) | 1,565,574 | |
| Volume/Avg Volume (20 Days) Ratio | 0.75 | |
| 52 Week Range | 27.97 - 121.06 | |
| Price vs 52 Week High | -69.79% | |
| Price vs 52 Week Low | 30.75% | |
| Range | 0.00 | |
| Gap Up/Down | -1.09 | |
Profitibility | ||
| Market Capitalization (Mln) | 4,282 | |
| Revenue per share | 0.0000 | |
| Net Income per share | -3.7558 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -9.7370 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
05/07 16:01 EST - globenewswire.com
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability...
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability...
05/01 08:00 EST - globenewswire.com
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical...
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical...
04/10 14:10 EST - zacks.com
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.
04/01 08:25 EST - zacks.com
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.
03/31 15:39 EST - seekingalpha.com
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity
Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It is expected that the 7 major pneumococcal disease markets are to reach a value of $11.6 billion by...
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity
Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It is expected that the 7 major pneumococcal disease markets are to reach a value of $11.6 billion by...
03/31 08:56 EST - benzinga.com
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Vaxcyte Inc. PCVX on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Pfizer Inc's...
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Vaxcyte Inc. PCVX on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Pfizer Inc's...
03/31 07:00 EST - globenewswire.com
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include...
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include...
03/30 17:00 EST - globenewswire.com
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow,...
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow,...
02/26 03:26 EST - seekingalpha.com
Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript
Vaxcyte, Inc. (NASDAQ:PCVX ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Andrew Guggenhime - President and CFO Grant Pickering - CEO Jim Wassil - EVP and COO Conference Call Participants Roger Song - Jefferies Salim Syed - Mizuho Umer Raffat - Evercore Seamus...
Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript
Vaxcyte, Inc. (NASDAQ:PCVX ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Andrew Guggenhime - President and CFO Grant Pickering - CEO Jim Wassil - EVP and COO Conference Call Participants Roger Song - Jefferies Salim Syed - Mizuho Umer Raffat - Evercore Seamus...
02/25 16:01 EST - globenewswire.com
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Company Expects to Announce Topline Safety, Tolerability and...
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Company Expects to Announce Topline Safety, Tolerability and...
02/12 16:05 EST - globenewswire.com
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth...
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth...
02/05 08:00 EST - globenewswire.com
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster...
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster...
01/30 16:05 EST - globenewswire.com
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside...
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside...
01/30 11:51 EST - globenewswire.com
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders...
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders...
01/15 07:15 EST - seekingalpha.com
Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
Vaxcyte's stock surged 68% since August 2023, driven by progress with its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. VAX-31, covering 95.6% of serotypes, has been selected over VAX-24 for Phase 3 trials, with topline data expected in 2026. Vaxcyte's robust financial position,...
Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
Vaxcyte's stock surged 68% since August 2023, driven by progress with its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. VAX-31, covering 95.6% of serotypes, has been selected over VAX-24 for Phase 3 trials, with topline data expected in 2026. Vaxcyte's robust financial position,...
12/03 08:00 EST - globenewswire.com
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later -- -- VAX-31 is Designed to Cover Approximately 94% of Invasive...
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later -- -- VAX-31 is Designed to Cover Approximately 94% of Invasive...
11/12 07:30 EST - globenewswire.com
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: Breakthrough Therapy Designation Granted by FDA; Company Plans to Initiate Adult Phase 3 Pivotal,...
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: Breakthrough Therapy Designation Granted by FDA; Company Plans to Initiate Adult Phase 3 Pivotal,...
11/05 16:01 EST - globenewswire.com
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Older -- -- PCV Adult Indication: VAX-31 Selected to Advance to Phase 3 Program; Initiation of Phase...
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Older -- -- PCV Adult Indication: VAX-31 Selected to Advance to Phase 3 Program; Initiation of Phase...